The Trump administration's proposed rule change to give political appointees more control over science funding is a deeply troubling development. This move threatens to undermine the very foundation of American scientific progress and innovation. The rule, if enacted, would grant unprecedented political influence over research grants, potentially derailing decades of progress in fields like public health, vaccine testing, biotechnology, social and behavioral science, and climate science.
One of the most alarming aspects of this proposal is the potential end of peer review as the gold standard in scientific evaluation. Peer review has been a cornerstone of the U.S. scientific community since the post-World War II era, ensuring the integrity and quality of research. However, the new rule would require political appointees, not scientists, to review grants before awards are made. This effectively gives these political officials veto power, even over projects that have already passed rigorous scientific peer review.
The implications of this change are far-reaching. It could lead to the dismantling of entire fields of study, as the administration seems determined to prioritize its own ideological agenda. The proposed rule also officially bans research on diversity, equity, and inclusion, and places broad prohibitions on international scientific collaborations, which are crucial for many high-impact studies.
The reaction from scientists and advocacy groups has been swift and vehement. Some compare this moment to the McCarthy era, where political ideology trumped scientific merit. The historian Tim Snyder, for instance, warns of a potential Stalinist situation where non-scientists make critical decisions about scientific funding.
The Trump administration justifies the rule change as a means to improve efficiency and combat waste, fraud, and abuse. However, critics argue that the existing peer-review system is already effective, and empowering political actors to make decisions about science is dangerous. They question the wisdom of allowing non-scientists like Russell Vought to determine the fate of groundbreaking research, such as new cancer therapeutics.
Congress is unlikely to take direct action on this rule change, as the proposed rule is open for public comment until July 13. After that, the OMB will review comments before deciding on a final version. If enacted, it will likely face legal challenges, as many believe it threatens the very essence of American scientific progress and the trust in science that has long been a cornerstone of the nation's success.
